Since its establishment in 2016, Shanghai Jinwei Biotechnology Co., Ltd. (Jinwei) has been at the forefront of biotechnology, dedicated to developing breakthrough treatments for serious and life-threatening diseases. We focus on key areas such as oncology, immunology, and infectious disease treatment, striving to bring hope to more patients through relentless technological advancements and product development.
Jinwei has built partnerships with leading international pharmaceutical companies, research institutions, and medical centers, including TheraVectys, the Pasteur Institute. Together, we are pioneering cutting-edge therapies for cancers as well as major infectious diseases like hepatitis B.
As participant in projects led by the Ministry of Science & Technology and China National Health Commission, we actively contribute to the prevention and control of infectious diseases.
READ MORE
We develop leading edge therapies for various cancers by combining next-generation In-silico Neoantigen Identification Methods with Built-in lentiviral vector-based platform.
READ MORE
As a CDMO, we offer effective solutions from clinical trials to commercialization, as well as delivery of safe and reliable viral vectors to accommodate our customers' needs.
READ MORE
Contact Us